Home
Learn More
Release Features
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 4, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
 
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for July 14, 2004 Subscribe to this News Feed      
 

Emerging Mesothelioma Treatments

New approach to treating mesothelioma cancer based on using light to kill cancer cells; more mesothelioma treatment options to follow.

Los Angeles, CA (PRWEB) July 14, 2004 -- Because mesothelioma is a newly publicized disease, many doctors may have a hard time diagnosing and treating it. Depending on the stage of the disease, the most common treatments are surgical removal of the affected tissues, chemotherapy, or radiation. There is some concern that research into mesothelioma will be minimal, because it is projected to be a short-lived disease in terms of new cases after the next 30 years. However, new research is consistently providing physicians with alternate forms of therapy, and there are many intense studies into control and cure of the disease, so those diagnosed with mesothelioma do have many options and a lot of hope.

Photodynamic therapy is a new approach to treating mesothelioma cancer and is based on using light to kill the cancer cells. In photodynamic therapy, a drug is first administered intravenously that targets and renders the cancerous cells more sensitive in a number of days. The drug is easily eliminated by normal cells, ensuring that they will not be harmed when light therapy is given. After the cells have been given the proper time of exposure to the drug, a special frequency of light laser beams are directed towards the mesothelioma cancer with the intent to eradicate it from the body without having to use more invasive methods. Although there are occasional cases of eye sensitivity and nausea and/or vomiting, the main side effect of photodynamic therapy is skin sensitivity after the procedure is completed.

More information on photodynamic therapy can be found on new Web site, Mesothelioma Help ( http://www.mesohelp.net ) The Web site contains several informative articles, including a primer on emerging treatments for mesothelioma.

The Web site was a joint product of Orbis Marketing and Jimandi Corp. Said editor Jimmy Atkinson, "We wanted to make a site that can actually help those coping with mesothelioma, rather than just another 'A-OK #1 Spam' site. This is a hard thing to face, and it's sad to see ambulance-chasers dominating this field. We aim to change that with Mesothelioma Help."

Orbis Marketing is a privately held company based in Los Angeles, California. For more information, please visit http://www.orbismarketing.com . Visit Jimandi Corp at http://www.dotmarketer.com . Visit Mesothelioma Help at http://www.mesohelp.net .

# # #

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web



OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Jim Atkinson
Orbis Marketing
(818) 716-2739
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright